ABP-1130

N/A

Report date: 2024/07/02 14:10:34

NME

Base Information

Drug NameABP-1130

Drug Alias NameABP-1130

ClassificationSmall molecules

Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsHepatocyte growth factor receptor inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists +[4]

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Tyrosine-protein kinase BTK +[4]

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesAb Pharma Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAb Pharma Ltd

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A